Bruce was appointed as Chief Executive Officer, effective 13 November 2020. Prior to that he was one of 2 Chief Operating Officers In this role he was responsible for the company’s discovery, clinical development, program management, CMC and business development functions related to Small Molecule Therapeutics.
An accountant by training, he has spent over two decades working in the life sciences and pharmaceutical industry. He has more than fourteen years’ experience with Liminal and has held a number of senior global positions across the organisation.
Prior to being appointed CEO he became COO in 2014, previously he was the Group CFO, a role he had held since 2008. Bruce brings a proven track record of success in strategic acquisitions and in raising debt and equity finance.
An accountant by training, he has spent over two decades working in the life sciences and pharmaceutical industry. He has more than fourteen years’ experience with Liminal and has held a number of senior global positions across the organisation.
Prior to being appointed CEO he became COO in 2014, previously he was the Group CFO, a role he had held since 2008. Bruce brings a proven track record of success in strategic acquisitions and in raising debt and equity finance.
Speaking In
10:30 AM - 10:45 AM (EST)
Tuesday, February 7
Liminal BioSciences is a development-stage biopharmaceutical company focused on developing…
Winter Garden
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
